Trial Profile
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 May 2022
Price :
$35
*
At a glance
- Drugs Fenfluramine (Primary) ; Cannabidiol
- Indications Dravet syndrome; Lennox-Gastaut syndrome
- Focus Adverse reactions
- Sponsors Zogenix
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 02 Jun 2020 Planned End Date changed from 1 Feb 2020 to 1 Aug 2020.
- 02 Jun 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Aug 2020.